TechConnect Innovation Program

Boron-based integrin-linked kinase (ILK) inhibitors for therapeutic and diagnostic uses

University of Kansas, KS, United States

TECHNOLOGY SUMMARY

Novel compounds and a method of treatment to reduce cyst growth in Polycystic Kidney Disease (PKD). The compounds target a key cellular pathway involved in aberrant proliferation in PKD, cancer, and neurological disorders. Compounds are synthesized using a unique approach to improve drug efficacy, specificity, solubility and cellular uptake.

Primary Application Area: Pharmaceuticals & Personal Care

Technology Development Status: Prototype

Technology Readiness Level: TRL 4

FIGURES OF MERIT

Value Proposition: Unique composition of matter patent application. Drug screenings showed the compounds inhibiting cell proliferation in nanomolar concentrations.

SHOWCASE SUMMARY

Organization Type: Academic/Gov Lab

Showcase Booth #: 13M

Website: www.kuic.ku.edu

GOVT/EXTERNAL FUNDING SOURCES

Government Funding/Support to Date:

Primary Sources of Funding: University

Looking for: Both Funding and Development Partners